Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TST001 in Advanced or Metastatic Solid Tumors
NCT04396821Phase 2Active, not recruiting
- Sponsor
- Transcenta
- Start
- May 2020
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of osemitamab in solid tumor, gastric cancer (GC), gastroesophageal junction cancer and 1 more (5 arms), sponsored by Transcenta. Primary endpoints: Adverse Events at 100 days and Maximum Tolerated Dose or Recommended Phase 2 Dose at 100 days. Started May 2020; status: active, not recruiting.
02
Drugs
osemitamab
03
Conditions
solid tumorgastric cancer (GC)gastroesophageal junction cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04396821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04396821.